Literature DB >> 23332604

Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool.

Patrick M Lynch1, Jeffrey S Morris, William A Ross, Miguel A Rodriguez-Bigas, Juan Posadas, Rossa Khalaf, Diane M Weber, Valerie O Sepeda, Bernard Levin, Imad Shureiqi.   

Abstract

BACKGROUND: Accurate measures of the total polyp burden in familial adenomatous polyposis (FAP) are lacking. Current assessment tools include polyp quantitation in limited-field photographs and qualitative total colorectal polyp burden by video.
OBJECTIVE: To develop global quantitative tools of the FAP colorectal adenoma burden.
DESIGN: A single-arm, phase II trial. PATIENTS: Twenty-seven patients with FAP. INTERVENTION: Treatment with celecoxib for 6 months, with before-treatment and after-treatment videos posted to an intranet with an interactive site for scoring. MAIN OUTCOME MEASUREMENTS: Global adenoma counts and sizes (grouped into categories: <2 mm, 2-4 mm, and >4 mm) were scored from videos by using a novel Web-based tool. Baseline and end-of-study adenoma burden results were summarized by using 5 models. Correlations between pairs of reviewers were analyzed for each model.
RESULTS: Interobserver agreement was high for all 5 measures of polyp burden. Measures that used both polyp count and polyp size had better interobserver agreement than measures based only on polyp count. The measure in which polyp counts were weighted according to diameter, calculated as (1) × (no. of polyps <2 mm) + (3) × (no. of polyps 2-4 mm) + (5) × (no. of polyps >4 mm) had the highest interobserver agreement (Pearson r = 0.978 for two gastroenterologists, 0.786 and 0.846 for the surgeon vs each gastroenterologist). Treatment reduced the polyp burden by these measurements in 70% to 89% of patients (P < .001). LIMITATIONS: Phase II study.
CONCLUSION: This novel, Web-based polyp scoring method provides a convenient and reproducible way to quantify the global colorectal adenoma burden in FAP patients and a framework for developing a clinical staging system for FAP.
Copyright © 2013 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23332604      PMCID: PMC3574220          DOI: 10.1016/j.gie.2012.11.038

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  3 in total

1.  Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis.

Authors:  Nicholas J West; Susan K Clark; Robin K S Phillips; John M Hutchinson; Roger J Leicester; Andrea Belluzzi; Mark A Hull
Journal:  Gut       Date:  2010-03-26       Impact factor: 23.059

2.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

Authors:  G Steinbach; P M Lynch; R K Phillips; M H Wallace; E Hawk; G B Gordon; N Wakabayashi; B Saunders; Y Shen; T Fujimura; L K Su; B Levin; L Godio; S Patterson; M A Rodriguez-Bigas; S L Jester; K L King; M Schumacher; J Abbruzzese; R N DuBois; W N Hittelman; S Zimmerman; J W Sherman; G Kelloff
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

3.  Standards of care in diagnosis and testing for hereditary colon cancer.

Authors:  Patrick M Lynch
Journal:  Fam Cancer       Date:  2007-08-16       Impact factor: 2.375

  3 in total
  6 in total

Review 1.  Chemoprevention of familial adenomatous polyposis.

Authors:  Patrick M Lynch
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

2.  Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis.

Authors:  Peiying Yang; Xiangsheng Zuo; Shailesh Advani; Bo Wei; Jessica Malek; Rena Sue Day; Imad Shureiqi
Journal:  Cancer Prev Res (Phila)       Date:  2022-04-01

Review 3.  Chemoprevention of hereditary colon cancers: time for new strategies.

Authors:  Luigi Ricciardiello; Dennis J Ahnen; Patrick M Lynch
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

4.  A proposed staging system and stage-specific interventions for familial adenomatous polyposis.

Authors:  Patrick M Lynch; Jeffrey S Morris; Sijin Wen; Shailesh M Advani; William Ross; George J Chang; Miguel Rodriguez-Bigas; Gottumukkala S Raju; Luigi Ricciardiello; Takeo Iwama; Benedito M Rossi; Maria Pellise; Elena Stoffel; Paul E Wise; Lucio Bertario; Brian Saunders; Randall Burt; Andrea Belluzzi; Dennis Ahnen; Nagahide Matsubara; Steffen Bülow; Niels Jespersen; Susan K Clark; Steven H Erdman; Arnold J Markowitz; Inge Bernstein; Niels De Haas; Sapna Syngal; Gabriela Moeslein
Journal:  Gastrointest Endosc       Date:  2016-01-06       Impact factor: 9.427

5.  Assessing barriers to a rational chemoprevention trial design in young patients with familial adenomatous polyposis.

Authors:  Joanna P Wood; Lynne M Howells; Karen Brown; Anne L Thomas
Journal:  Eur J Cancer Prev       Date:  2017-07       Impact factor: 2.497

6.  Cold snare polypectomy effectively reduces polyp burden in familial adenomatous polyposis.

Authors:  Nedhi J Patel; Prasanna L Ponugoti; Douglas K Rex
Journal:  Endosc Int Open       Date:  2016-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.